Loading stock data…
Spruce Biosciences, Inc. (SPRB)
$55.88+0.77 (+1.40%)
After Hours$53.25-2.63 (-4.71%)· Last close Jun 29
Spruce Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spruce Biosciences, Inc. in the Healthcare sector is trading at $55.88 with a market capitalization of $141M. Wall Street consensus targets $149.71 (7 analysts), implying a +167.9% move over the next 12 months. The stock is currently near its 52-week low of $7.00, remaining 23.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +167.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.99M↓ | -$11.10M↓ | -$8.23M↓ | -$2.69M↑ | -$14.49M |
| Net Income | -$12.27M↑ | -$14.65M↓ | -$8.21M↓ | -$2.07M↑ | -$14.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$141.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-107.34%
Volume
Today's trading volume
79,344
Recent News
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Dynatrace, Emerson Electric, Exxon Mobil, Flutter Entertainment, Genuine Parts, nVent Electric, Palantir Technologies, Roku, and More
Pre-Market Stock Futures: Futures are trading modestly higher after a stunning opening to the week, as all major indices rocketed higher. The announcement of a cease-fire deal with Iran, which the leaders in that country acknowledged, called for reopening the Strait of Hormuz toll-free. While details will still be worked out over the next ... Here Are Tuesday’s Best Wall Street Analyst Research Calls: Dynatrace, Emerson Electric, Exxon Mobil, Flutter Entertainment, Genuine Parts, nVent Electric,
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss
Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s transition toward its next phase of growth. Hooks brings nearly 35 years of biopharmaceutical experience to the role, having overseen 21 new product […]